Efficacy News and Research

RSS

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

Biological-based therapies are alternative medicines for women recovering from breast cancer

Biological-based therapies such as diet supplements and vitamins are the most popular complementary and alternative medicines for women recovering from breast cancer, according to a Michigan State University researcher working to create a support intervention for women in treatment for the disease.

12 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen.

11 Feb 2010

Microbial risk management in food processing needs to be improved within EU countries

Microbial risk management is difficult and very important in food processing and although we have common EU legislation for food producers microbial risk management needs to be improved and harmonized within EU countries. Microbial risk management consists of several parts. Knowledge of hygienic design and factory layout can prevent severe microbial hazards.

11 Feb 2010

Seminar held in Tallinn provides information about hygienic design and cleaning procedures

Hygiene in food processing factories is highly dependent on hygienic design of the process lines and equipment as well as on cleaning efficiency. Principles of hygiene design are simple but several faults appear in food processing premises. Hygienically designed process lines are supposed to be cleanable but still optimization of cleaning programs is worthwhile.

11 Feb 2010

VCU professor warns consumers to be wary of unregulated electronic cigarettes

Electronic cigarettes should be evaluated, regulated, labeled and packaged in a manner consistent with cartridge content and product effect - even if that effect is a total failure to deliver nicotine as demonstrated in a study supported by the National Cancer Institute and led by a Virginia Commonwealth University researcher.

11 Feb 2010

People with GAD have abnormalities in the way their brain unconsciously controls emotions

People with generalized anxiety disorder, or GAD, have abnormalities in the way their brain unconsciously controls emotions. That's the conclusion of a new Stanford University School of Medicine study, and the study authors say the findings could open up new avenues for treatments and change our understanding of how emotion is regulated in everyday life.

11 Feb 2010

UC experts recommend binational prevention efforts for TB and HIV infections

The results of an innovative study to understand what factors may influence who contracts tuberculosis (TB)/HIV co-infection in San Diego show a significant shift in the ethnic makeup of the disease, with the majority of cases now coming from the Hispanic community.

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Elbit Imaging Ltd. announces that its associated company (approximately 28% holding on a fully diluted basis), Gamida Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV), announced today that the Data Monitoring Committee ("DMC") has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.

10 Feb 2010

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)—the leading therapy in the psoriasis drug market in 2008—will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Feb 2010

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical Corp., today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a poster titled, "Correlation of Plasma Cysteamine and WBC Cystine Levels at Steady State in Patients Treated with Cysteamine Bitartrate." The results will also be published in an upcoming issue of the journal Molecular Genetics and Metabolism.

10 Feb 2010

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

10 Feb 2010

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences Inc., announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024.

10 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Efficacy News and Research

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Biological-based therapies are alternative medicines for women recovering from breast cancer

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Microbial risk management in food processing needs to be improved within EU countries

Seminar held in Tallinn provides information about hygienic design and cleaning procedures

VCU professor warns consumers to be wary of unregulated electronic cigarettes

People with GAD have abnormalities in the way their brain unconsciously controls emotions

UC experts recommend binational prevention efforts for TB and HIV infections

Micromet outlines the design of registration study for blinatumomab in ALL

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

YM BioSciences receives additional AeroLEF patents in U.S.

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News